Oculis Holding (OCS) Price & Analysis

Compare

78 Followers

OCS Stock Chart & Stats

$21.75

$0.20(1.10%)

At close: Jan 08 4:00 PM EST

$21.75

$0.20(1.10%)

Day’s Range― - ―

52-Week Range$14.00 - $23.08

Previous CloseN/A

Volume95.89K

Average Volume (3M)55.28K

Market Cap

$1.18B

Enterprise Value$814.84M

Total Cash (Recent Filing)$160.30M

Total Debt (Recent Filing)$1.03M

Price to Earnings (P/E)―

Beta0.27

Next Earnings

Nov 10, 2025

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.61

Shares Outstanding54,533,672

10 Day Avg. Volume119,797

30 Day Avg. Volume55,277

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.69

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-7.67

Forecast

1Y Price Target

$37.60

Price Target Upside72.87% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Market PotentialAON market opportunity is valued over $3 billion, with potential blockbuster expansion into NAION.

Regulatory ProgressFDA alignment on protocol that matches ACUITY increases probability of success to 60%.

Scientific AdvancementOCS-05 demonstrated statistically significant and clinically meaningful improvements in anatomical, biological and visual endpoints of AON, buttressing its potential as a disease-modifying and neuroprotective therapy for AON.

Bears Say

Delay In ResultsData from the announced PIONEER phase 3 trials for OCS-05 are unlikely to deliver results until 2028.

Market CompetitionOCS-05 has vast potential given that there has been little-to-no success in developing treatments that can provide neuroprotection for neuro-ophthalmic and neurologic diseases.

Pricing ConcernsPrivosegtor may be priced above $100,000 per treatment if successfully developed and approved.

Oculis Holding News

Oculis price target raised to $51 from $33 at Chardan

Chardan raised the firm’s price target on Oculis (OCS) to $51 from $33 and keeps a Buy rating...

11d ago

OCS

Oculis price target raised to $30 from $28 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Oculis (OCS) to $30 from $28 and keeps...

12d ago

OCS

Oculis price target raised to $36 from $33 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen raised the firm’s price target on Oculis (OCS) to $36 from $33 and...

12d ago

OCS

Oculis Advances Privosegtor into Registrational Trials for Neuro-Ophthalmology

Oculis Holding ( ($OCS) ) has shared an announcement. On October 6, 2025, Oculis Holding AG announced the...

12d ago

OCS

Oculis Holding: Strategic Advancements and Market Potential Drive Buy Rating

Oculis Holding, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from...

12d ago

OCS

Oculis initiated with a Buy at Needham

Needham initiated coverage of Oculis (OCS) with a Buy rating and $36 price target Lead-asset OCS-01 aims to...

2M ago

OCS

Nvidia reportedly stops H20 AI chip output for China: Morning Buzz

The major averages were sharply higher near noon as U.S. Federal Reserve Chair Jay Powell said in his...

2M ago

Oculis price target raised to $33 from $32 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $33 from $32 and keeps a Buy...

2M ago

OCS

Oculis Holding: Buy Rating Backed by Strong Financials and Promising Clinical Pipeline

In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Oculis...

2M ago

OCS

Oculis Holding AG Reports Q2 2025 Financial Progress

Oculis Holding Ag ( ($OCS) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

OCS

Oculis Holding Reports Strong Financial Position in Mid-2025

Oculis Holding ( ($OCS) ) has shared an announcement. On August 21, 2025, Oculis Holding AG announced its...

2M ago

OCS

Oculis reports Q2 EPS (49c), consensus (43c)

Riad Sherif, CEO of Oculis (OCS), stated: “We maintain a strong focus on execution to advance our portfolio...

2M ago

OCS

OCS Upcoming Earnings Report: What to Expect?

Oculis Holding Ag (OCS) is scheduled to report 2nd quarter earnings on 08/19/2025. Regarding Q2 estimates, Wall Street...

2M ago

OCS

Oculis Holding AG Secures Amended Loan Agreement with Kreos Capital

Oculis Holding ( ($OCS) ) has issued an update. Oculis Holding AG, a company based in Zug, Switzerland,...

3M ago

OCS

OCS FAQ

What was Oculis Holding’s price range in the past 12 months?

Oculis Holding lowest stock price was $14.00 and its highest was $23.08 in the past 12 months.

What is Oculis Holding’s market cap?

Oculis Holding’s market cap is $1.18B.

When is Oculis Holding’s upcoming earnings report date?

Oculis Holding’s upcoming earnings report date is Nov 10, 2025 which is in 22 days.

How were Oculis Holding’s earnings last quarter?

Oculis Holding released its earnings results on Aug 21, 2025. The company reported -$0.612 earnings per share for the quarter, missing the consensus estimate of -$0.512 by -$0.1.

Is Oculis Holding overvalued?

According to Wall Street analysts Oculis Holding’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oculis Holding pay dividends?

Oculis Holding does not currently pay dividends.

What is Oculis Holding’s EPS estimate?

Oculis Holding’s EPS estimate is -0.52.

How many shares outstanding does Oculis Holding have?

Oculis Holding has 54,533,672 shares outstanding.

What happened to Oculis Holding’s price movement after its last earnings report?

Oculis Holding reported an EPS of -$0.612 in its last earnings report, missing expectations of -$0.512. Following the earnings report the stock price went up 0.281%.

Which hedge fund is a major shareholder of Oculis Holding?

Currently, no hedge funds are holding shares in OCS

Oculis Holding Stock Smart Score

Neutral

Fundamentals

Return on Equity

-80.98%

Trailing 12-Months

Asset Growth

47.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oculis Holding

Oculis Holding (OCS) is a biopharmaceutical company focused on the development of innovative treatments for eye diseases. The company operates primarily in the ophthalmology sector, specializing in drug delivery systems and therapies aimed at addressing a range of ocular conditions. Oculis is committed to advancing its proprietary technologies to improve patient outcomes and enhance the quality of life for individuals suffering from vision impairments.

Oculis Holding (OCS) Earnings & Revenues

Historic Earnings Reports

OCS Stock 12 Month Forecast

Average Price Target

$37.60

▲(72.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","31":"$31","52":"$52","20.5":"$20.5","41.5":"$41.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,20.5,31,41.5,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.4,19.984615384615385,22.569230769230767,25.153846153846153,27.738461538461536,30.323076923076922,32.90769230769231,35.49230769230769,38.07692307692308,40.66153846153846,43.246153846153845,45.830769230769235,48.41538461538462,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.4,18.953846153846154,20.507692307692306,22.06153846153846,23.615384615384613,25.16923076923077,26.723076923076924,28.276923076923076,29.83076923076923,31.384615384615387,32.93846153846154,34.49230769230769,36.04615384615385,{"y":37.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.4,18.369230769230768,19.338461538461537,20.307692307692307,21.276923076923076,22.246153846153845,23.215384615384615,24.184615384615384,25.153846153846153,26.123076923076923,27.092307692307692,28.06153846153846,29.03076923076923,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.76,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.45,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >